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Almanac 2012: Interventional Cardiology
PASCAL MEIER1 AND ADAM TIMMIS2
From 1The Heart Hospital, University College London Hospitals UCLH; 2London Chest Hospital, Barts and the
London School of Medicine and Dentistry, London, UK
MEIER AND TIMMIS.: Almanac 2012: Interventional cardiology. The field of interventional cardiology continues
to progress quickly. The efficacy of percutaneous interventions with newer generation drug-eluting stents has advanced
a lot over the last decade. This improvement in stent performance has broadened the level of indication towards more
complex interventions such as left main and multi- vessel PCI. Major improvements continue in the field of medical
co-therapy such as antiplatelet therapies (bivalirudin, prasugrel, ticagrelor) and this will further improve outcomes of
PCI. The same is true for intravascular imaging such as ultrasound IVUS and optical coherence tomography OCT.
However, interventional cardiology has become a rather broad field, also including alcohol septal ablation for
hypertrophic obstructive cardiomyopathy, etc. At the moment, the fastest growing area is the structural interventions,
especially for aortic valve stenosis (transcatheter aortic valve implantation TAVI) and for mitral regurgitation (mitral
clipping). This review covers recent advances in all these different fields of interventional cardiology. (J HK Coll
Cardiol 2013;21:1-14)
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PCI

PCI
TAVI

Percutaneous Coronary Intervention
Versus Medical Treatment

Address for reprints: Dr. Pascal Meier
The Heart Hospital, University College London Hospitals UCLH,
16-18 Westmoreland Street, London, United Kingdom
Email: pascalmeier74@gmail.com
Received November 29, 2012; accepted January 25, 2013
*The article was first published in Heart 2012;98(23):1701-9.
doi: 10.1136/heartjnl-2012-302569. Epub 2012 Sep 2. Review and
is republished with permission.
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Percutaneous coronary intervention (PCI) has
guideline recommendations for treatment of ST
elevation and non-ST elevation myocardial infarction
(MI).1 However, its role in stable coronary disease has
been the subject of reappraisal following publication
of the COURAGE trial, which showed that, in patients
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receiving optimal medical therapy, PCI does not improve
cardiovascular outcomes, while incremental benefits for
quality of life disappear by 36 months.2,3 A more recent
meta-analysis of eight trials of optimal medical therapy
versus PCI involving 7229 patients bears out the
COURAGE conclusions by showing no significant
differences between the groups with regard to death
(9.1% vs 8.9%), non-fatal MI (8.1% vs 8.9%), unplanned
revascularisation (30.7% vs 21.4%) and persistent angina
(33% vs 29%).4 Drug-eluting stents (DESs) were used
in only a minority of these patients and may have reduced
the need for further revascularisation while improving
symptomatic responses. Nevertheless, the meta-analysis
reinforces contemporary guideline advice for optimal
medical treatment as the initial treatment for stable
angina. 5 Whether this will change current practice
remains to be seen, but early signs are not encouraging.
Thus a US registry analysis of patients undergoing
PCI before (n=173 416) and after (n=293 795) the
COURAGE report showed no change in the proportions
receiving optimal medical treatment (43.5% vs 44.7%).6

investigators. 12 However, CABG may have the
advantage of providing prognostic benefit, recent US
registry data showing a lower 4-year mortality compared
with PCI (16.4% vs 20.8%) in an analysis that adjusted
for selection bias.13 Of course, being a registry study,
treatment allocation was not random and any
conclusions about relative prognostic benefits require
caution. Nevertheless, guideline recommendations are
for surgery in complex three-vessel and left main stem
disease, although many patients continue to express a
preference for PCI, particularly now we have reports of
the feasibility and safety of same-day discharge. This is
particularly applicable with radial access (or postprocedural deployment of a femoral closure device),
and, in a US registry study, 1339 patients discharged
on the same day as their procedure had similar 30-day
readmission rates to 105 679 patients who stayed
overnight. 14 This is important because it is now
recognised that readmission within 30 days after PCI is
associated with a significant increase in 1-year mortality.15

Left Main Stem Disease
PCI Versus Coronary Bypass Surgery
The safety of PCI at hospitals without on-site
cardiac surgery has been confirmed in two recent
reports. 7,8 Add to this the feasibility of PCI in
increasingly complex disease and we need look no
further to explain the substantial reductions in rates of
coronary bypass surgery (CABG) in recent years. A
recent US study of revascularisation procedures during
2001-2008 showed a 38% decline in rates of CABG,
while PCI decreased by only 4%.9 Some have questioned
whether patients are being appropriately advised
according to contemporary guidelines,10 a US analysis
of 500 154 PCIs reporting that, among the 28.9% of
cases performed for non-acute indications, only 50.4%
were appropriate and that angina was not present in
many of the inappropriate cases.11 In the absence of any
evidence of prognostic benefit, there can be no indication
for PCI in stable patients without angina. In patients
with angina, on the other hand, PCI is as effective as
CABG in providing symptom relief at 12 months,
judging by a recent report from the SYNTAX

2

The trespass of PCI on to territory that was
formerly surgical is best illustrated by its increasing
application in unprotected left main stem disease.
Registry data from the USA for 131 004 patients with
unprotected left main stem disease show the proportion
treated with PCI increasing from 3.8% to 4.9% between
2004 and 2008. PCI recipients were older with more
comorbidities, probably accounting for their higher
hospital mortality compared with the overall cohort
(13% vs 5%).16 Technical improvements since 2008 have
seen further increases in rates of PCI in unprotected left
main stem disease, and we now have randomised trial
data confirming its safety and efficacy in selected
patients. Thus in the KoreanPRECOMBAT trial of drugeluting stenting versus CABG in 600 patients, 8.7% of
patients in the stent group and 6.7% in the CABG group
met the primary end point (a composite of death, MI,
stroke and ischaemia-driven revascularisation at 12
months), a difference significant for the non-inferiority
of stenting.17 As in previous randomised comparisons,
the difference was driven largely by a higher rate of
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repeat revascular- isation in stent recipients (9.0%
vs 4.2% after 2 years, p=0.02).
Selection for revascularisation in left main stem
disease has traditionally been based on angiographic
assessment, but a recent study suggests that
measurement of minimum lumen area by intravascular
ultrasound (IVUS) might be a better means of selection
in patients with 'intermediate' angiographic stenoses in
the range 25-60%.18 Correlation between minimum
lumen area and angiographic stenosis was poor, but a
6 mm2 area measurement provided a safe threshold for
determining revascularisation, the event-free survival
being no worse in the patients with an area measurement
>6 mm 2 who did not undergo revascularisation
compared with the patients with an area measurement
<6 mm2 who did. These were non-randomised data, but
point to a useful role for IVUS in the management of
left main coronary artery disease.

DESs and Stent Thrombosis
The introduction of bare metal stents (BMSs)
towards the end of the last decade dramatically improved
the performance and safety of PCI, but it required drugeluting technology to make a significant impact on
restenosis rates. Concerns about an increased risk of
stent thrombosis with DESs 19 appear to have been
exaggerated, particularly with the current generation of
DESs, but the beneficial effects on restenosis have been
borne out. Thus a recent meta-analysis comparing
sirolimus-eluting and bare metal stents in patients with
diabetes reported dramatic reductions in the need for
repeat revascularisation with the DES (HR 0.27, 95%
CI 0.18 to 0.41) without any increase in the risk of stent
thrombosis.20 However, it has been the everolimuseluting stent that has emerged as the interventionists'
favourite, a meta-analysis of 13 randomised trials
including 17 101 patients reporting thrombosis rates of
only 0.7% during 21.7 months' follow-up, compared
with 1.5% in patients treated with any other type of DES.21
A further meta-analysis pooled data from 49 randomised
trials including 50 844 patients and came to similar
conclusions by showing that everolimus-eluting stents
had the lowest risk of stent thrombosis at 30 days and 1
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year compared with other stents approved for use in the
USA, including BMSs.22 The difference in favour of
everolimus-eluting stents remained significant at 2 years
when the odds of stent thrombosis was 0.34 (95% CI
0.19 to 0.62) compared with paclitaxel-eluting stents
and 0.35 (95% CI 0.17 to 0.69) compared with BMSs.
Data on DESs in saphenous vein grafts are
somewhat less clear, but the limited available
randomised trials do suggest superiority compared with
BMSs.23 For primary PCI, concerns that the thrombotic
environment might predispose to DES thrombosis have
not been fully realised, a pooled analysis of 15 STEMI
trials comparing first-generation DESs with BMSs
reporting a lower requirement for target vessel
revascularisation with DESs (RR 0.51, 95% CI 0.43 to
0.61), with no difference in the rate of stent thrombosis
compared with BMSs. 24 Indeed, the risk of stent
thrombosis during the first year was reduced for DESs
(RR 0.80, 95% CI 0.58 to 1.12) but increased thereafter
(RR 2.10, 95% CI 1.20 to 3.69), suggesting that the early
benefit of first-generation DESs in primary PCI is offset
by a later increase in the risk of stent thrombosis. Newergeneration DESs may overcome this drawback, but, until
we have sufficient data, operators should carefully weigh
the differential risk of reste-nosis and stent thrombosis
between the two stent types.
Interest in bioresorbable stents has been enhanced
by reports from a phase II evaluation of imaging data
12 months after implantation in 56 patients. 25 The
restenosis rate was only 3.5%, and >95% of the stent
struts were endothelialised. Moreover, variable coronary
dilatation in response to acetylcholine was observed,
indicating some return of normal vasomotor responses.
The results of randomised trials now in the planning
stage are eagerly awaited.

Optimal Arterial Access
Radial access for coronary angiography has now
achieved widespread application.26,27 One reason is the
accumulating evidence that it reduces bleeding risk and,
perhaps because of this, may reduce mortality in primary
PCI.28 Thus a comprehensive meta-analysis pooling all
the data from randomised primary PCI trials comparing
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femoral with radial access showed a nearly 50%
mortality reduction in the radial group.29 Whether this
beneficial effect is generalisable to everyday clinical
practice is unclear, but observational data support the
trial results and indicate benefit of radial access for
primary PCI. 30,31 Another potentially important
advantage of radial access is its association with a
reduced risk of kidney injury, as reported in a large
Canadian study of 69 214 patients undergoing cardiac
catheterisation.32 The mechanism is unclear and the
largest trial comparing radial and femoral access, the
RIVAL trial, did not show a clear advantage for either
access route, although radial access appeared preferable
in the subgroup undergoing primary PCI.33 On the basis
of current evidence, the choice between radial and
femoral access should be individualised taking into
account operator experience, bleeding risk and patient
preference.

Antiplatelet Therapies − What's New?
In patients undergoing PCI, dual antiplatelet
therapy with aspirin and clopidogrel remain central to
guideline recommendations. For clopidogrel, a pooled
analysis of available data favoured a loading dose of
600 mg, which was associated with a 34% reduction in
the rate of major adverse cardiac events (MACE)
without any increase in the risk of major bleeding
compared with a 300 mg loading dose.34 Now we have
randomised trial evidence confirming that, compared
with the 300 mg loading dose, the 600 mg dose in
primary PCI is associated with significant reductions in
infarct size, measured by median CKMB mass over
72 h (2070 vs 3029 ng/ml).35 Continuing therapy with
aspirin and clopidogrel is usually recommended after
PCI in both stable and patients with acute coronary
syndromes (ACS), but the antiplatelet effect of
clopidogrel is variable, and high on-treatment platelet
reactivity can be demonstrated in 14.7-26.9% of patients,
depending on the test used.36 Part of this variability in
antiplatelet responsiveness is explained by the fact that
clopidogrel is a prodrug, and the enzymes that form its
active metabolites exhibit functionally distinct
polymorphisms. However, a study from the Netherlands

4

of 1069 clopidogrel-pretreated patients undergoing
elective PCI found that loss-of-function CYP2C19
carrier status explained only part of the variability in
platelet reactivity (13.0-20.6%), depending on the test
used.37 One approach to modifying high on-treatment
platelet reactivity in carriers of loss-of-function
CYP2C19 variants is to use antiplatelet drugs
metabolised by different pathways, and this was
confirmed by investigators from Korea in a substudy of
the CILON-T randomised trial.38 In patients with lossof-function CYP2C19 variants who were randomised
to dual antiplatelet therapy plus cilostazol, a selective
phosphodiesterase-3 inhibitor, on-treatment platelet
reactivity was significantly reduced compared with
patients who received only aspirin and clopidogrel. This
effect of cilostazol was not seen in non-carriers of the
loss-of-function polymorphism. An alternative approach
for modifying high on-treatment platelet reactivity after
PCI is to increase the dose of clopidogrel. However,
this was found ineffective in the GRAVITAS trial, the
6-month rate of the composite of cardiovascular death,
MI and stent thrombosis being identical for groups
randomised to high-dose (150 mg daily) or standarddose (75 mg daily) clopidogrel.39
Current guideline recommendations are for
clopidogrel to be stopped 12 months after DES
deployment when endothelialisation is complete,
reducing the risk of thrombosis. Worryingly, a clustering
of late clinical events has been associated with this
policy, perhaps because of an increase in arachidonic
acid-induced platelet activation as reported in a recent
UK study, 40 lending support to the accumulating
evidence that clopidogrel exerts some of its antiplatelet
effects via this pathway, independently of aspirin.
Indeed, it has been suggested that discontinuation of
aspirin instead of clopidogrel might be more rational 1
year after stenting.41 This question will soon be tested
in the large GLOBAL-LEADERS randomised trial. The
limitations of dual antiplatelet therapy with aspirin and
clopidogrel have been further illustrated by the onTIME-2 trial, in which patients undergoing primary PCI
were randomised to additional prehospital tirofiban or
placebo.42 The addition of tirofiban produced more
effective platelet inhibition than aspirin and clopidogrel
alone, and this was associated with a reduction in MACE
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and early stent thrombosis. On-TIME-2 lends further
support to guideline recommendations for early
glycoprotein IIb/IIIa inhibition together with dual
antiplatelet therapy in patients undergoing primary PCI.

Newer P2Y12 Receptor Inhibitors
These include prasugrel and ticagrelor, which
now have guideline indications in ACS43 based on the
TRITON and PLATO randomised trials, which were
the subject of recent review.44 TRITON randomised
patients undergoing PCI for ACS to either clopidogrel
or prasugrel therapy for 12 months after the proce- dure.45
Prasugrel showed superiority over clopidogrel for the
composite primary end point, driven mainly by
periprocedural MI. It also showed significant risk
reduction for stent thrombosis. However, these benefits
came with an increased risk of major and minor
bleeding. In the PLATO trial of ticagrelor versus
clopidogrel in patients with ACS managed medically
or with PCI,46 ticagrelor was superior with regard to the
primary composite end point of MACE, but, while minor
bleeding was more common with ticagrelor, the major
bleeding risk was comparable to that with clopidogrel.
These randomised trials have confirmed that more
intensive platelet inhibition with prasugrel or ticagrelor
delivers better clinical outcomes in ACS, although there
is a bleeding penalty, particularly it seems for prasugrel.
The clinical outcome advantage for both drugs is small
in absolute terms, raising important questions about costeffectiveness. A US evaluation for prasugrel concluded
it was 'an economically attractive treatment strategy',47
but a more recent National Institute for Health and
Clinical Excellence (NICE) technology assessment was
more guarded, recommending prasugrel as an option in
patients with STEMI if immediate primary PCI is
necessary (based on its rapid onset of action compared
with clopidogrel), or if diabetes is present or if stent
thrombosis has occurred during clopidogrel treatment.43
However, concern was expressed about its likely costeffectiveness in other situations. A recent healtheconomic analysis based on the PLATO study concluded
that treating patients with ACS with ticagrelor for 12
months is associated with a cost per QALY (qualityadjusted life year) below generally accepted thresholds
for cost-effectiveness.48

J HK Coll Cardiol, Vol 21

Bivalirudin and Heparin
Bivalirudin is now available for treatment of ACS
and has rapidly gained a central role in primary PCI.49
It is a direct thrombin inhibitor with additional activity
against thrombinmediated platelet activation that
showed superiority over a combined regimen of heparin
plus a glycoprotein IIb/IIIa inhibitor in HORIZONSAMI, due largely to a lower rate of major bleeding (4.9%
vs 8.3%). All-cause mortality was lower at 30 days, and
we now have 3-year follow-up data confirming
persistent mortality benefit (5.9% vs 7.7%), ensuring a
guideline recommendation for bivalirudin in primary
PCI.50 The clinical benefits of bivalirudin have also been
associated with cost-effectiveness, patient lifetime costs
in the UK being £267 lower than for glycoprotein IIb/
IIIa inhibitors. 51 A small increase in rates of stent
thrombosis with bivalirudin was not seen in patients
pretreated with heparin, and the mortality benefits of
combining bivalirudin with heparin pretreatment have
since been reported from the SCAAR registry,52 leading
the editorialist to recommend dual therapy in patients
undergoing primary PCI.53
Unfractionated heparin retains a class 1
recommendation for use during PCI, but a recent metaanalysis of pooled data from 23 studies has shown that
enoxaparin is associated with significant reductions in
the composite of death and MI and in major bleeding
rates compared with unfractionated heparin.54 These
benefits were greatest for primary PCI, but were also
seen in PCI for non-ST elevation MI and stable angina.
The time may be right for a change of policy in favour
of low-molecular-weight heparin during PCI.

Intravascular Imaging − Clinical Benefit?
The clinical benefit of using IVUS to guide PCI
remains controversial, although a pooled analysis of
seven randomised BMS trials has concluded that IVUSguided PCI is associated with a reduced risk of in-stent
restenosis.55 IVUS is also finding a role in assessing
left main stem lesions for revascularisation. 18 As a
research tool, however, and for validation of noninvasive imaging of coronary stenosis, IVUS has proved
particularly valuable. 56 Thus, in a recent study
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comparing coronary CT angiography and IVUS for
plaque volume measurements, there was only modest
agreement between the two methods (Bland-Altman
limits of agreement -67 to +65 mm3), reflecting the
limitations of coronary CT for assessing the extent of
coronary disease.57 While the ability to image across
the coronary arterial wall is a particular strength of
IVUS, the technology is limited by image resolution,
which is considerably inferior to optical coherence
tomography (OCT). In a substudy of ODESSA, for
example, suboptimal stent deployment was identified
by OCT at the level of individual stent struts, a detail
that could never be reproduced by IVUS.58 Increasingly,
OCT is being used to assess stent strut endothelialisation,
a recent Japanese study of everolimus-eluting stent
implantation showing that, of 5931 struts assessed, 98.4%
were endothe- lialised 8 months after implantation, an
observation reflected in the low thrombotic risk for these
second-generation DESs.59
Intravascular imaging has also been used to assess
plaque stability, the PROSPECT trial confirming that
IVUS can differentiate stable from unstable plaque and
predict adverse events.60 A key feature of unstable plaque
is thin-cap atherosclerosis, and recent data remind us
that the inflammatory environment is an important
determinant of instability, an OCT study showing a clear
association between the cap thickness of plaques and
inflammatory plasma markers such as high-sensitivity
C-reactive protein.61

Bifurcation Stenting
Several studies have shown that a single, main
vessel stent deployment provides outcomes that are
comparable-and often superior-to two-stent deployment.
Thus a combined analysis of the NORDIC Bifurcation
Study and the British Bifurcation Coronary Study
showed that, in patients randomised to 'simple' main
vessel stenting, the composite MACE end point at 9
months occurred in 10.1% of patients compared with
17.3% of patients who underwent complex two-vessel
stenting (p=0.001). 63 However, questions remain,
particularly concerning the value of final kissing balloon
inflations across the bifurcation following main-vessel
stenting. This was addressed in a large observational
study of 1055 patients undergoing bifurcation stenting.64
A comparative propensity analysis of patients who did
and did not have final kissing balloon inflations showed
a higher incidence of MACE and target lesion
revascularisation, mostly in the main vessel, for patients
who had final kissing balloon inflations. The pendulum
therefore has now swung away from final kissing
balloon inflation, which may cause more harm than
good.

Myocardial Infarction −
High-Sensitivity Troponin Assays

Technical Aspects of Stenting −
What Have We Learnt?
Overlapping Stents
Re-endothelialisation of overlapping stent
segments is slower, and most operators prefer single
stent deployment for that reason.58 However, in the real
world, overlapping stent deployment is often
unavoidable, and, for DESs, the conventional wisdom
has been that homogeneous stents should be used to
avoid elution of different pharmacological compounds
within the overlapping segment. This has now been
challenged by a Korean study of 1080 patients who
received overlapping DESs.62 The study showed that
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cardiac death, MI or target lesion revascularisation
occurred with similar frequency regardless of whether
the DESs were homogeneous or heterogeneous.

Central to the diagnosis of acute MI is the
demonstration of a raised and changing troponin
concentration in the first 24 h after symptom onset. The
availability of high-sensitivity troponin (hsTn) assays
is likely to see diagnostic thresholds fall, with important
implications for clinical management and cardiac
outcomes. Thus, in a recent study in which hsTn-I was
measured in 1038 patients with suspected ACS, values
below the previous limit of detection (0.20 ng/ml)
showed graded association with death or non- fatal MI.65
In a further 1054 patients, the diagnostic threshold was
lowered to 0.05 ng/ml, and attending physicians were
invited to modify their management accordingly. Rates
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of death and recurrent MI fell from 39% to 12% among
patients with troponin concentrations 0.05-0.19 ng/ml,
levels that would have been undetectable with
conventional troponin assays. The investigators
concluded that lowering the diagnostic threshold using
hsTn assays has the potential to identify many highrisk individuals with suspected ACS and produce major
improvements in their prognosis.
It has always been the recommendation that the
diagnostic threshold level chosen for troponin should
be based on a coefficient of variation of #10%, but new
guidance is for the 99th centile value to be adopted
regardless of assay imprecision.66 The potential clinical
impact of this change in guidance was evaluated in the
same cohort as reported previously,65 this time using a
diagnostic threshold of 0.012 µg/l (coefficient of
variation 20.8%)67 At 1 year, patients with troponin
concentrations of 0.012-0.049 µg/l, who previously
would have escaped a diagnosis of MI, were more likely
to be dead or readmitted with recurrent MI than those
with troponin concentrations <0.012 µg/l (13% vs 3%,
p<0.001). The authors concluded that lowering the
diagnostic threshold to the 99th centile and accepting
greater assay imprecision would identify more patients
at high-risk of recurrent MI and death, but increase the
diagnosis of MI by 46%. It remains to be established
whether reclassification of these patients and treating
them according to conventional MI guidelines will
improve their outcomes.
hsTn assays will not only cause diagnostic
thresholds for acute MI to fall, but may also allow
identification of patients with apparently stable coronary
disease who have vulnerable coronary lesions.68 Thus a
recent study has shown a strong correlation between
hsTn-T and non-calcified plaque burden (r=0.79,
p<0.001) in 124 patients with stable angina undergoing
CT angiography, patients with remodelled non-calcified
plaque having the highest hsTn-T values.69 hsTn assays
have already found clinical application for the early
diagnosis of MI in patients with chest pain attending
the emergency department. In the Randomised
Assessment of Treatment using Panel Assay of Cardiac
Markers (RATPAC) trial, the use of hsTn-I within a
panel of biomarkers allowed successful discharge of
32% of patients compared with 13% of patients
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receiving standard diagnostic procedures.70 Beyond their
central role for diagnosis, troponins also provide a
measure of the severity of MI, and, in a report from the
GRACE registry,71 incorporating 16 318 patients with
non-ST elevation MI, each 10-fold increase in the
troponin ratio was associated with stepwise increments
in ventricular arrhythmias, heart failure, cardiogenic shock
and death.72

Non-Culprit Lesions in ACS
The importance of myocardial salvage during the
acute phase of infarction is emphasised by the fact that
prognosis is driven largely by ultimate infarct size. We
could therefore hypothesise that treating all significant
lesions is beneficial. One of the first primary PCI
randomised trials testing this hypothesis was reported
last year. Among 214 patients with multivessel disease,
adverse event rates during a mean follow-up of 2.5 years
were higher with culprit-only PCI compared with
multivessel PCI, whether performed during the index
procedure or as a staged procedure afterwards. 73
However, the trial was small and not definitive, a
more recent meta-analysis finding in favour of
culprit-only primary PCI with a staged strategy for
non-culprit lesions.74 This has become the guideline
recommendation and was further supported by
analysis of observational data from the HORIZONSAMI trial in which outcomes for 275 patients treated
with single-procedure stenting were compared with
outcomes for 393 patients treated with staged
procedures. 75 The single-procedure group received
significantly more stents yet had a significantly higher
12 month mortality (9.2% vs 2.3%) than the staged
procedure group. The weight of evidence is now firmly
in favour of culprit-only stenting during primary PCI.

Infarct Size and Myocardial Salvage
Circadian rhythms in the onset of MI are well
established, the morning hours being the period of
greatest risk. Intriguingly, infarct size appears to show
similar circadian variation, a retrospective analysis of
811 patients with STEMI showing that creatine kinase
(CK) and troponin I curves peak between 06:00 h and
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noon.76 Myocardial salvage in response to reperfusion
therapy with PCI is the major strategy for limiting infarct
size therapeutically and can now be quantified by
cardiovascular magnetic resonance (CMR). A study of
208 patients presenting with STEMI confirmed that the
extent of salvage measured by CMR is closely related
to long-term prognosis, patients with a myocardial
salvage index (MSI) above the median level having a
lower number of adverse cardiovascular events (7 vs
26) and deaths (2 vs 12) after 18.5 months than patients
with MSI below the median level. 77 Myocardial
reperfusion, however, can itself exacerbate injury, by a
variety of mechanisms which include interstitial
haemorrhage. This can be detected by CMR and was
reported in 25% of patients with STEMI treated
successfully by primary PCI. 78 The presence of
haemorrhage was an independent predictor of adverse
remodelling, as reflected by increased left ventricular
(LV) end-systolic volume at 3 months. The importance
of interstitial haemorrhage as a predictor of LV
remodelling was emphasised by the improvement in the
area under the receiver operating characteristic curves
from 0.699 to 0.826 when it was added to LV ejection
fraction and infarct size in the predictive model.
Microvascular obstruction after primary PCI is also
predictive of remodelling, and in another CMR study
was found to correlate significantly with reperfusion
haemorrhage (r2=0.87, p<0.001).79
Strategies to protect against reperfusion injury
remain high on the research agenda and have been the
subject of recent review.80 In one study the effect of
erythropoietin was tested based on beneficial
experimental effects for reducing infarct size. 81
However, the study was negative, with patients
randomised to erythropoietin (50 000 IU) before primary
PCI showing an increased incidence of microvascular
obstruction and LV dilatation without reduction in
infarct size compared with patients randomised to
placebo. Another study using forearm plethysmography
tested a bradykinin B2 receptor antagonist, based on
the hypothesis that endogenous bradykinin is a mediator
of reperfusion injury.82 The investigators found that
remote ischaemic preconditioning abolished the
impairment of endothelium-dependent vasomotor
function induced by plethysmography, but bradykinin
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receptor blockade had no effect. Nevertheless, the
finding that conditioning stimuli provide a clinically
applicable means of protection against reperfusion injury
was not new and has been replicated in other more recent
clinical trials. A comparative primary PCI study of postconditioning by staccato reversus abrupt reperfusion,
for example, showed that the staccato protocol was
associated with better preservation of microvascular
function and LV dimensions 12 months later.83 Staccato
reperfusion was also partially effective in another
primary PCI study in which patients were randomised
to staccato reperfusion versus control. Infarct size was
unaffected, except in patients with large areas at risk in
whom it was significantly reduced by post-conditioning.84
The benefits of intra-aortic balloon
counterpulsation (IABC) when cardiogenic shock
complicates acute MI are generally accepted. Recently,
the role of IABC for reducing infarct size in
haemodynamically stable patients with anterior MI was
tested in a randomised trial of 337 patients.85 Infarct
size at 3-5 days determined by MRI showed no
significant difference between the groups, but those
patients randomised to IABC showed a trend towards
more vascular complications. The authors concluded
that IABC produces no clinical benefit in this group of
patients.

Contrast-Induced Acute Kidney Injury
(CI-AKI)
Whether newer contrast agents, such as isoosmolar contrast, have an impact on the CI-AKI risk is
controversial.86 Risk of CI- AKI is particularly high in
patients presenting with an ACS, and recent data confirm
it has a significant impact on clinical outcomes,
including length of hospital stay and mortality.87,88 The
ACS setting offers little time to apply reno-protective
measures, and strategies requiring up to 12 h of
prehydration are clearly impractical. The need for a
change in practice was emphasised by Wi et al,87 who
concluded that renal function should be measured
at baseline and after primary PCI, to refine risk
stratification. Meanwhile consideration should be
given to reno-protection with bicarbonate, which has
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been reported to be more effective than normal saline
using short-infusion or singlebolus protocols. 89 In
certain subgroups, such as patients requiring urgent
surgery for infective endocarditis, preoperative coronary
angiography does not appear to increase the risk of acute
kidney injury,90 but, in general, contrast exposure should
be kept at as low a level as possible during primary
PCI. Meanwhile, randomised trials testing shortduration prehydration protocols or bolus applications
of potentially reno-protective substances are needed.

Carotid Artery Stenosis − Is Stenting Still
an Option?
Life style adjustment and secondary prevention
drugs may not always be effective in protecting against
progression of carotid atherosclerosis. A recent trial of
weight reduction with rimonabant, for example, reported
that a 5% reduction in body weight over 30 months failed
to influence the progression of carotid disease compared
with patients who received placebo.91 Many patients
therefore require an interventional solution to their
carotid disease, but whether this should be surgical or
percutaneous remains contentious.92 A large randomised
trial of 2502 patients with symptomatic or asymptomatic
carotid stenosis showed no significant difference in the
estimated rates of the primary composite end point
(periprocedural stroke, MI, or death or any ipsilateral
stroke within 4 years) and no differential treatment effect
by symptomatic status. 93 However, a recent metaanalysis pooling data from 11 randomised trials
comparing carotid endarterectomy (CEA) with carotid
artery stenting (CAS) showed that the periprocedural
risk of mortality or stroke was lower for CEA (OR 0.67,
95% CI 0.47 to 0.95), mainly driven by a decreased
risk of minor stroke, whereas the risk of death or
disabling stroke was similar between the two groups.
The odds of periprocedural MI or cranial nerve injury
were significantly higher in the CEA group.94 Current
NICE guidelines recognise CAS as a treatment option
for patients with symptomatic carotid artery stenosis,
but emphasise that patients need to understand the risk
of stroke and other complications associated with this
procedure. Patient selection should be carried out by a
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multidisciplinary team.95
For asymptomatic carotid artery disease, the
situation is even less clear. We know that patients with
carotid stenosis undergoing cardiac surgery for their
coronary artery disease have an increased periprocedural
stroke risk and probably should be considered for
treatment even if asymptomatic. The American
guidelines recommend CEA if the stenosis is ≥80%,
either before or combined with CABG. CAS before
CABG is an alternative option with good results in
patients who are considered 'high risk' for CEA. 96
Attempts to refine risk prediction in such patients have
been the subject of considerable research, a recent
carotid ultrasound study reporting that the total plaque
area (HR 1.29, 95% CI 1.08 to 1.55), the number of
plaques (HR 1.14, 95% CI 1.02 to 1.27) and the number
of segments with plaque (HR 1.45, 95% CI 1.09 to 1.93)
were all significantly associated with the 5-year risk of
cerebrovascular events.97

Transcatheter Aortic Valve Implantation
Transcatheter aortic valve implantation (TAVI)
in older high-risk patients has yielded excellent results
in most centres, the 2-year follow-up of patients in the
PARTNER trial supporting the procedure as an
alternative to surgery in high-risk patients. 98 Thus
improvement in valve areas was similar for TAVI and
for surgery, with comparable rates of death and stroke
during follow-up. However, paravalvular regurgitation
was more common after TAVI and has been associated
with significantly worse outcomes, the German registry
reporting higher in-hospital mortality, even after
multivariate adjustments for potential confounders (OR
2.50, 95% CI 1.37 to 4.55).99 Another cause for concern
is the potential for myocardial injury during TAVI, as
evidenced by elevations of CK-MB in 77% of 101
patients undergoing uncomplicated procedures. 100
Median maximal CK-MB levels were higher for
transapical than transfemoral access (22.6 ml vs 9.9 ml),
but were unaffected by the presence of coronary artery
disease. Elevations of cardiac troponin T were also
observed and were predictive of cardiac death at 9
months. Clearly, therefore, TAVI, like surgery, is
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commonly associated with some degree of myocardial
injury that is not benign. In most other respects,
however, TAVI appears safe and has been associated
with important symptomatic benefits, as reflected in the
improvement in health-related quality of life reported
by the PARTNER investigators.101 Smaller studies have
reinforced these findings by reporting improvement in
the 6 min walk distance and quality of life scores, while
brain natriuretic peptide (BNP) levels decline
substantially.102 Add to this the cost-effectiveness of
TAVI in US and UK analyses, and it seems certain that
indications will continue to expand.103,104 Indeed, offlabel TAVI is commonplace, with reported outcomes
that are comparable to on-label procedures. 105
Paradoxically, increasing TAVI activity appears to have
led to a significant increase in referrals for surgical aortic
valve replacement,106 with Manchester, for example,
seeing a 37% increase in surgical AVR activity within
the 2 years of starting a TAVI programme.107

Percutaneous Mitral Valve Repair
The development of percutaneous systems for
mitral valve repair in patients with severe mitral
regurgitation has proved more challenging than TAVI.
NICE gave a guarded verdict on the MitraClip device in
2010, recommending it only be used with 'special
arrangements for clinical governance, consent and
research for patients who are well enough for surgical
mitral valve leaflet repair'.108 This was based on the
findings of the Endovascular Valve Edge-to-Edge REpair
Study (EVEREST) investigators in an observational
study of 107 patients with moderate or severe mitral
regurgitation, which reported a successful MitraClip
implant in 74% of patients, of whom 66% achieved
freedom from death, mitral valve surgery and severe
mitral regurgitation (≥3+).109 Since then the EVEREST
investigators have undertaken a further observational
study in 78 older patients at high risk of conventional
surgery, which showed that the MitraClip device reduced
mitral regurgitation in the majority of patients, with
improvement in symptoms associated with significant
LV reverse remodelling over 12 months.110 The benefits
of the MitraClip appear closely related to its efficacy in
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reducing mitral regurgitation, the midterm outcomes
showing significant association with the acute
haemodynamic response.111

Alcohol Septal Ablation in Hypertrophic
Cardiomyopathy
Three studies have recently reported longer-term
outcomes after alcohol septal ablation in symptomatic
patients with hypertrophic cardiomyopathy (HCM). The
results have been encouraging. Among 874 patients with
class III or IV symptoms in a US study, six (0.7%)
died in relation to the procedure, and survival estimates
at 1, 5 and 9 years were 97%, 86% and 74%,
respectively.112 Symptoms improved to class I or II in
all but 5% of cases, although 13% required repeat
ablation and 3% required surgical myomectomy. In a
Canadian study of 649 patients with HCM, 38% were
managed conservatively, and 62% underwent invasive
therapy with alcohol septal ablation (21%), surgical
myomectomy (71%) or dual chamber pacing (8%).113
In multivariate analysis, invasive therapy was
independently associated with better overall survival
(HR 0.6; 95% CI 0.4 to 0.97, p=0.04), but not with
HCM-related survival. Among the invasive group, the
pacemaker-treated group fared less well than patients
treated with septal ablation or myomectomy,
questioning the call for a reappraisal of pacemaker
therapy in a recent Spanish study that reported
favourable long-term results in a group of 50
patients. 114 Finally, a Scandinavian study reported
marked reductions in outflow tract gradients in response
to 313 ablation procedures in 279 patients with HCM,
of whom 94% had class III/IV symptoms.115 Only 21%
had class II/IV symptoms at 1 year, with little change
thereafter. Estimated survival rates at 1, 5 and 10 years
were 97%, 87% and 67%, respectively, and were
comparable to survival rates in an age- and gendermatched population. Taken together, these studies testify
to the long-term benefits of alcohol septal ablation in
HCM, which appears to be a valid alternative to surgery
in symptomatic HCM that does not respond to medical
therapy.
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Dabigatran as Alternative Anticoagulant for Intra-Aortic Balloon
Pump in a Patient with Suspected Heparin-Induced Thrombocytopenia
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LEE ET AL.: Dabigatran as Alternative Anticoagulant for Intra-Aortic Balloon Pump in a Patient with Suspected
Heparin-Induced Thrombocytopenia. Heparin induced thrombocytopenia (HIT) is an uncommon condition but can
result in devastating outcomes. Alternative anticoagulants are recommended for HIT patients with on-going needs of
anticoagulation. We report a case of cardiogenic shock treated with intra-aortic balloon pump. The patient was
complicated with isolated HIT after administration of low-molecular-weight heparin, and was successfully managed
with dabigatran, an oral direct thrombin inhibitor, as an alternative anticoagulant. (J HK Coll Cardiol 2013;21:
15-20)
Anticoagulation, Dabigatran, Heparin, Heparin-induced thrombocytopenia, Intra-aortic balloon pump
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Introduction
Two types of heparin-induced thrombocytopenia
(HIT) have been described. Type 1 HIT is a nonimmunogenic form of HIT and occurs more
commonly. It usually occurs within the first 2 days
after heparin administration and platelet counts often
return to normal despite continuation of heparin. The
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immune-mediated (type 2) HIT is of clinical importance.
In the rest of the article, the term HIT refers to immunemediated HIT unless otherwise specified. In susceptible
patients receiving heparin, HIT antibodies are formed
and bind to heparin-platelet factor 4 (PF4) complexes.
Such an interaction triggers platelets activation and
aggregation, and therefore leads to thrombocytopenia
and thrombotic phenomenon in HIT. Patients who are
using unfractionated heparin have an absolute risk
of 2.6% to develop HIT, although the use of lowmolecular-weight heparin may reduce the risk by tenfold.1 Among patients with acute coronary syndrome
using heparin, a similar incidence rate of 1.6% is
reported.2 The occurrence is uncommon but the clinical
consequence can be severe. Therefore heparin, being a
substrate to cause HIT, should be discontinued in these
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patients. However it is frequently compelling to continue
anticoagulation for the initial indications of
heparinization, for examples, in patients requiring
haemodynamic support from intra-aortic balloon pump
(IABP) and extracorporeal membrane oxygenation.
Anticoagulation should also be continued in patients
with HIT, as thrombosis prophylaxis or as treatment of
established thrombosis if any. Different classes of
anticoagulants other than heparin, including direct
thrombin inhibitors (lepirudin, bivalirudin, argatroban),
synthetic pentasaccharide (fondaparinux), and direct
factor-Xa inhibitor (danaparoid) have been shown to
be useful alternatives in such patients who are
contraindicated to heparin.3-8 Unfortunately, these agents
are not readily available in some parts of the world,
including in our locality. We report the use of dabigatran,
an oral direct thrombin inhibitor (DTI), as an alternative
anticoagulant in a patient on IABP who developed
isolated HIT after administration of low-molecularweight heparin. To our knowledge, the clinical evidence
describing the use of dabigatran in patients with HIT is
scarce. Dabigatran may have both advantages and
disadvantages over other anticoagulants in managing
patients with HIT.

Case Report
A 70-year-old man was admitted to the hospital
for anterior ST elevation myocardial infarction, with
the presenting symptom of chest pain. He developed an
episode of witnessed cardiac arrest due to ventricular
fibrillation in the Emergency Department and the
arrhythmia was promptly aborted by external
defibrillation. The patient developed shock with blood
pressure of 77/62 mmHg. He was also intubated and
mechanically ventilated for respiratory failure.
Electrocardiogram showed sinus rhythm and 2 mm
ST segment elevation over the anterior chest leads.
Severe pulmonary congestion was noted on chest
X-ray. The patient was started on dopamine and an IABP
was inserted for haemodynamic support. An urgent
coronary angiogram showed a total thrombotic
occlusion at the left main coronary artery. Primary PCI
was performed, with a drug-eluting stent implanted to
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the left main artery. In view of the high thrombus load,
a bolus dose of intra-coronary eptifibatide was given,
followed by intravenous infusion over the next 24 hours.
The patient was started on double antiplatelet agents,
by loading aspirin 320 mg and clopidogrel 600 mg,
followed by regular doses of aspirin 80 mg daily and
clopidogrel 75 mg daily. He was also started on
intravenous furosemide for diuresis, intravenous
amoxicillin-clavulanate for possible secondary chest
infection, intravenous ranitidine as prophylaxis for stress
peptic ulcer, and subcutaneous tinzaparin 12,000
anti-Xa units every 24 hours (based on the patient's
body weight 63 kg) as anticoagulant for the IABP.
Subsequent blood tests showed a sudden and
remarkable drop of platelet counts, from 166x109/L on
admission, to a trough level of 59x109/L on the fifth
day of hospitalization (Figure 1). The red and white
cell counts, prothrombin time and activated partial
thromboplastin time (aPTT) were unremarkable. His
renal function was normal, with creatinine level of 63
umol/L (estimated creatinine clearance 85.8 mL/min).
Such a late drop of platelet counts was considered
unlikely due to IABP-related thrombocytopenia or the
use of glycoprotein IIb/IIIa inhibitor. Because of the
timing (on day 5 after the administration of lowmolecular-weight heparin) and the degree of drop in
platelet counts (more than 50% drop than baseline level)
with no obvious alternative explanation, a diagnosis of
isolated HIT was suspected. Clinically there was no
overt bleeding, skin necrosis or thromboembolic
event, although doppler ultrasound had not been
performed to detect any clinically silent deep vein
thrombosis. The 4T's score for HIT was 5 (2 points for
thrombocytopenia, 2 points for timing of platelet
count fall, 0 points for thrombosis or other sequelae,
1 point for other causes for thrombocytopenia
present, as the use of IABP and eptifibatide may cause
thrombocytopenia but less likely in this case), indicating
the intermediate probability of HIT.9 Functional assay
for platelet activation, or immunoassay for heparin-PF4
antibodies were not performed as confirmatory tests
because they were not readily available in our hospital.
Therefore tinzaparin was taken off and dabigatran
(PRADAXA , Boehringer Ingelheim, Germany)
110 mg was given every 12 hours via the feeding tube
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as an alternative anticoagulant for the IABP. Clotting
profile was checked 4.5 hours after initiation of
dabigatran and the aPTT prolonged from the baseline
24 seconds to 42 seconds (reference: 24-38 seconds),
which was believed due to the anticoagulation effect
from dabigatran. The aPTT remained prolonged in the

following few days when the patient was still on
dabigatran. The continuous heparin saline flush through
the IABP was also switched to normal saline. The
platelet counts gradually improved and normalized on
the fifty day after putting on dabigatran. The patient
showed clinical improvement and was able to wean off

Ranitidine 50mg q8h iv
Simvastatin 20mg QD po
Clopidogrel 75mg QD po*
Aspirin 80mg QD po†
Amoxicillin/clavulanate 1000/200mg q8h iv
Morphine & midazolam infusion
Furosemide iv
Dabigatran 110mg BD po
Tinzaparin 12,000 anti-Xa units QD sc
Eptifibatide iv‡
Dopamine infusion iv
Intra-aortic balloon pump

*Loading dose 600 mg on Day 1
†Loading dose 320 mg on Day 1
‡Intra-coronary bolus 12 mg during PCI, followed by 8 mg/hr iv infusion
Abbreviation: q8h (every 8 hours); iv (intravenous); QD (daily); po (per oral); BD (twice daily); sc (subcutaneous)
Figure 1. The list of medications administered, in conjoint with the trend of platelet counts in the first 12 days of hospitalization.
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the IABP on day 9. Dabigatran was stopped once the
IABP was taken off. Further anticoagulation was not
contemplated, in view of absence of clinical thrombotic
event and the bleeding risk associated with the
concomitant use of double antiplatelet agents after
implantation of a drug eluting stent. He was wean off
the mechanical ventilation soon afterwards. He made
good progress in rehabilitation and was discharged after
32 days of hospitalization. No clinical thrombotic event
was noted during the disease course and recovery period.

Discussion
Non-heparin anticoagulants, including lepirudin,
bivalirudin, argatroban, fondaparinux, and danaparoid,
are used to treat HIT. However there is not much clinical
evidence describing the use of novel oral anticoagulants
for this indication. Fieland and Taylor have reported
the use of dabigatran for stroke prevention in a patient
with non-valvular atrial fibrillation who developed
thrombocytopenia after coronary artery bypass graft
surgery. The patient was subsequently found to have
heparin-PF4 antibodies.10 However the clinical diagnosis
of HIT in this case was not established, in view of the
absence of thrombotic event, low probability of HIT as
defined by the 4T's score, and the possible confounding
effects on thrombocytopenia and heparin-PF4 antibodies
by cardiopulmonary bypass.11 In our case report, we
describe the use of dabigatran as an alternative
anticoagulation regimen in a patient with clinically
diagnosed isolated HIT and yet required ongoing
anticoagulation for the IABP. We endorsed the 110 mg
twice daily dosage as we took reference from the RELY
trial that this dosage was non-inferior to warfarin for
stroke prevention in patients with non-valvular atrial
fibrillation.12 We avoided the 150mg twice daily dose
in view of the bleeding risk associated with the
concomitant use of double antiplatelet agents. Another
reason to use the 110 mg, instead of 150 mg, twice daily
dose is that administration of crushed dabigatran
pellets without the capsule shell increases the oral
bioavailability by 75%, which can precipitate bleeding
complication.13 For this reason the manufacturer advises
against taking the drug with the capsule broken, chewed
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or opened. We still decided to give crushed dabigatran
pellets via the feeding tube in this patient because we
were left with no treatment option, as those non-heparin
parental anticoagulants were not available in our unit.
Dabigatran has the properties of reversible, rapid
and selective inhibition of thrombin. It is rapidly
absorbed from oral route and once absorbed, the prodrug dabigatran etexilate is converted to the biologically
active form dabigatran. Dabigatran is approved for the
use of stroke prevention in non-valvular atrial
fibrillation, and deep vein thrombosis prophylaxis after
orthopaedic surgery.12,14 We believe that dabigatran,
being an univalent DTI, can act like other parenteral
DTIs to exert an anticoagulation effect, and at the same
time not precipitating or aggravating the pathological
process of HIT. It is supported by the fact that the
molecular structures of dabigatran and other parenteral
DTIs are dissimilar to that of heparin, making the DTI
unlikely to form complexes with PF4 and then to trigger
platelet activation. The parenteral DTIs have not been
shown to cause the pathological processes of HIT.15
Similarly, a recent in-vitro study also demonstrated that
dabigatran does not potentiate the interactions of PF4
or anti-heparin-PF4 antibodies with platelets, supporting
its practical use in patients with acute or history of HIT.16
Compared with other non-heparin anticoagulants
which have established roles in HIT, dabigatran has
several potential advantages: dabigatran has predictable
pharmacokinetic and pharmacodynamic profiles, and at
the same time it provides therapeutic anticoagulation
effect with large safety margin.17 Therefore it can be
taken with a fixed dosage, and blood tests for the purpose
of drug titration is non-essential for approved
indications. The property of reversible binding to
thrombin may also provide a better side effect profile
when compared with other DTIs with irreversible
thrombin binding, such as lepirudin. DTI with reversible
thrombin binding leaves a small amount of free,
enzymatically active thrombin available for control of
haemostasis.17,18 The better risk-benefit ratio is seen in
an experimental model, in which melagatran, also a
reversible thrombin binder, provides a lower bleeding
risk than irreversible thrombin binder hirudin. 19
Nevertheless, an effective antidote of dabigatran has not
yet been established. On-going anticoagulation for
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certain duration is usually required after the initial
thrombocytopenic phase in HIT, and these patients
are usually managed by switching the parental
anticoagulants to warfarin. The use of dabigatran can
omit this medication transition, and at the same time
offering benefit over warfarin by not requiring drug
titration.
For dabigatran being a drug in oral preparation,
the alterations of pharmacokinetics in critically ill
patients may make it less effective. Reduced gut motility
and diminished gastrointestinal tract perfusion due to
blood shunting occur in patients who are critically
ill, in shock or using inotropes. In general, such
physiological responses impede drugs absorption from
the gastrointestinal tract, and therefore lead to a delay
in achieving peak serum concentration, and possibly
lower total drugs exposure, i.e. smaller area under curve
for time and drugs concentration.20 As dabigatran is
administered twice daily, the trough plasma drug level
and therefore its anticoagulation effect are particularly
vulnerable to reach the subtherapeutic range when drug
absorption is impeded. In contrast, such a phenomenon
is less likely to occur in most of the parental
anticoagulants used for HIT treatment, which are
administered by continuous infusion with titration of
dosage according to the clotting profile. Acute kidney
injury is not uncommon in these critically ill patients
and can lead to diminished renal clearance of dabigatran,
which in turn increases the risk of adverse drug effects
such as bleeding. Although there is a lack of study
working specifically on the dabigatran pharmacokinetics
in critically ill patients, we may have some clues from
studies investigated on subjects who have undergone
orthopaedic surgery and have received dabigatran as
prophylaxis for deep vein thrombosis. The postoperative
physiological changes may resemble that of a critically
ill patient to some extent: Lower peak plasma dabigatran
level and a delay in reaching the plasma peak level are
found during the early postoperative period, when
compared with the healthy control subjects.21,22 Such
findings are considered due to reduced gastric motility
and gastric pH following surgery. We had not checked
the plasma dabigatran level or the ecarin clotting time
in our case to confirm adequate drug absorption and
therapeutic anticoagulation effect during the critically
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ill status. Having acknowledged the limitation of nonlinear relationship between aPTT and plasma dabigatran
level, we believe certain anticoagulation effect had been
exerted as suggested by the prolonged aPTT.
Eptifibatide can also cause thrombocytopenia.
The incidence of eptifibatide-induced moderate
thrombocytopenia (<100x109/L) is 3.8%, while severe
thrombocytopenia (<50x109/L) occurs uncommonly,
with an incidence of 0.6%23. In the presented case,
eptifibatide had been used on day 1 and 2, and the
onset of thrombocytopenia was on day 5. The use of
eptifibatide was unlikely the cause of thrombocytopenia,
as glycoprotein IIb/IIIa inhibitors-induced
thrombocytopenia occurs early, typically within 24
hours from the initiation of treatment. The use of IABP
is commonly associated with thrombocytopenia. It
appears that the occurrence of thrombocytopenia is
independent of the use of heparin, but instead the
mechanical force of IABP takes into account.24 IABPrelated thrombocytopenia usually takes place right after
the administration of IABP and the platelet counts drop
gradually to a nadir on day 3 to day 4.24-26 In our reported
patient, the pattern of stable platelet counts initially with
a sudden drop on day 5 was more compatible with HIT
instead of IABP-related thrombocytopenia. Although
the use of beta-lactam antibiotic can also cause
thrombocytopenia, the normalized platelet counts
despite continuation of amoxicillin-clavulanate rejected
the diagnosis of antibiotic-induced thrombocytopenia.
We did not performed any functional or antibodies assay
to ascertain the immune-mediated mechanism of HIT,
as patients having non-immune-mediated HIT (type 1)
usually do well when heparin is continued and need not
to have alternative anticoagulant. Nevertheless, the
molecular dissimilarity of dabigatran with heparin, and
the results of in-vitro molecular studies make dabigatran
a potential option in patients with HIT.15,16 More clinical
studies are required to prove its efficacy and safety in
HIT.

Conclusion
Several alternative anticoagulants have
established their roles in treating patients with HIT, but
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the drug supplies are not always available. The novel
oral DTI dabigatran has structural dissimilarity to
heparin. Its lack of interaction in the pathological
process of HIT make it a feasible option in treating
patients with HIT and a need of ongoing anticoagulation.
Because of its pharmacokinetic and pharmacodynamic
properties, dabigatran has both potential advantages and
disadvantages to the other anticoagulants.
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